Welcome to our dedicated page for Know Labs SEC filings (Ticker: KNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Researching Know Labs’ pathway to commercializing its Bio-RFID and ChromaID diagnostics often starts with one question: where in the SEC filings does the company discuss clinical milestones, FDA submissions, or cash runway? This page gathers every Know Labs filing—annual report 10-K, quarterly earnings report 10-Q, 8-K material events, proxy statements, and, crucially, insider trading Form 4 transactions—so you never hunt across EDGAR again.
Stock Titan’s AI engine reads each document the moment it hits EDGAR and produces plain-English highlights. Need the R&D expense trend from the last three quarters? Wonder how to read Know Labs’ 10-K without parsing 200 pages? Curious about “Know Labs insider trading Form 4 transactions” before a key regulatory update? Our AI answers these questions by spotlighting patent additions, executive stock awards, and any going-concern language—then links straight to the original text for audit trail peace of mind.
Use the filings the way professionals do:
- Track "Know Labs quarterly earnings report 10-Q filing" for burn-rate analysis
- Receive "Know Labs Form 4 insider transactions real-time" alerts to gauge management confidence
- Scan “Know Labs 8-K material events explained” for partnership or clinical-trial announcements
Whether you’re comparing quarter-over-quarter R&D, dissecting executive compensation in the proxy, or simply seeking “Know Labs SEC filings explained simply,” Stock Titan’s blend of comprehensive coverage and AI-powered summaries turns dense disclosures into actionable knowledge—so you can focus on understanding the company’s non-invasive diagnostics roadmap, not decoding legal prose.
Barclays Bank PLC is issuing $452,000 of unsecured, unsubordinated Buffered Supertrack SM Notes linked to the price return of the Russell 2000 Index (RTY). The notes are part of the bank’s Global Medium-Term Notes, Series A and will be offered in $1,000 denominations on 30 Jun 2025, maturing 30 Dec 2027.
- Payout profile – If the index is flat or up at maturity, investors receive principal plus 2× upside, capped at a 31.35 % maximum return ($1,313.50 per $1,000 note).
- Downside buffer – First 10 % decline is fully protected. Below the 90 % Buffer Value (1,922.57), losses are linear: every additional 1 % drop erodes 1 % of principal, up to a 90 % loss.
- Key parameters: Initial Value 2,136.185; Upside Leverage 2.0; Buffer 10 %; CUSIP 06746BX71; Estimated value on pricing date $965.70 (≈3.4 % below issue price).
- Costs & liquidity: 2.75 % selling commission; no exchange listing; Barclays Capital intends, but is not obliged, to make a secondary market.
- Credit & regulatory risk: Payments depend on Barclays’ creditworthiness and are subject to the U.K. Bail-in Power, meaning principal could be written down or converted to equity during resolution.
- Tax & withholding: Issuer views the notes as prepaid forward contracts; U.S. tax treatment uncertain; Section 871(m) not expected to apply (delta ≠ 1).
The structure targets investors who can forgo coupons, accept a capped return, and tolerate meaningful equity and issuer risk in exchange for a modest downside buffer and enhanced—though limited—upside participation.
Know Labs (KNW) has issued a preliminary proxy statement ahead of a virtual special meeting scheduled for July 24, 2025. Shareholders of record on June 20, 2025 will vote on four proposals:
- Authorized Share Increase (Proposal 1) – amendment of the Articles of Incorporation to expand authorized common stock from 7.5 million to 750 million shares.
- Private Placement (Proposal 2) – approval to issue shares exceeding 19.99 % of outstanding stock and the resulting change of control linked to a June 6, 2025 Securities Purchase Agreement with Goldeneye 1995 LLC.
- Equity Incentive Plan (Proposal 3) – increase the 2021 Plan share reserve by 35 million shares.
- Adjournment (Proposal 4) – authority to adjourn the meeting if necessary to secure sufficient votes.
The Board unanimously recommends voting “FOR” all proposals, citing enhanced capital flexibility and alignment of incentives. Materials will be mailed on or about July 3, 2025, and voting can be completed online, by telephone, or by mail.
If adopted, the proposals would provide significant funding capacity but also introduce substantial dilution risk—a 100-fold increase in authorized shares and a transaction that may transfer control to Goldeneye 1995 LLC.
Know Labs, Inc. (KNW) Schedule 13G – Insider ownership disclosure
Ronald P. Erickson, the company’s founder and long-time executive, together with his controlled entity J3E2A2Z LP (collectively the “Reporting Persons”), has filed a Schedule 13G indicating beneficial ownership of 1,492,092 common shares, equal to 19.99 % of Know Labs’ 7,497,948 outstanding shares as of 12 Jun 2025. The filing date that triggered the report is 06 Jun 2025; signatures are dated 20 Jun 2025.
Capital-structure details
- Direct holdings: 137,202 common shares
- Preferred: 16,916 Series H Preferred shares (issued 2 Jun 2025 via conversion of $1.184 million of convertible promissory notes) are convertible into 3,534,525 common shares.
- Warrants: 97,367 common-share purchase warrants outstanding.
However, the Series H Preferred and warrants are subject to a 19.99 % beneficial-ownership blocker; therefore only 1,492,092 shares are currently deemed beneficially owned. The filing certifies that the securities were not acquired to change or influence control of the issuer.
Key implications for investors
- The debt-to-equity conversion removes $1.18 million of obligations, strengthening the balance sheet.
- Insider alignment is high, with Erickson at the 20 % reporting threshold.
- Full conversion of Series H Preferred and warrants could add up to ~3.6 million new shares, a material dilution risk once the blocker is waived or exceeded.
FAQ
What is the current stock price of Know Labs (KNW)?
What is the market cap of Know Labs (KNW)?
What core technologies power Know Labs Inc's diagnostic solutions?
How do Know Labs' technologies improve patient care?
What is the primary business focus of Know Labs Inc?
In which industry does Know Labs Inc operate?
How does Know Labs differentiate itself from traditional diagnostic methods?
What potential applications arise from Know Labs' wearable diagnostic technology?
